-
The Medicines Company (MDCO) PT Lowered to $48 at Citi
-
The Medicines Company (MDCO) Seen as M&A Target Upon Clean Safety Data - Citi
-
The Medicines Company (MDCO) PT Raised to $50 at Citi
-
Citi Upgrades The Medicines Company (MDCO) to Buy
-
Medicines Co. (MDCO) to Sell its Infectious Disease Business Unit to Melinta Therapeutics (MLNT) for $270M
-
The Medicines Company Announces Definitive Agreement to Sell its Infectious Disease Business Unit to Melinta Therapeutics
-
Pre-Open Stock Movers 01/06: (ETRM) (OGXI) (STML) Higher; (RT) (GIII) (REGN) Lower (more...)
-
Notable Analyst Rating Changes 12/5: (V) (VNCE) (MCD) Upgraded; (KEY) (WCC) (VASC) Downgraded
-
Pre-Open Stock Movers 04/16: (MNOV) (TZOO) (NFLX) (PNRA) Higher; (PTX) (SNDK) (FNRG) Lower (more...)
-
Pre-Open Stock Movers 04/10: (GE) (HZNP) (NFLX) Higher; (EXTR) (MDCO) (CTXS) Lower (more...)
-
Notable Analyst Rating Changes 10/07: RBN, CRM, VIA-B, WFR Upgraded; COST, MDCO, CTL, DPS Downgraded
-
Citi Maintains a 'Buy' on The Medicines Company (MDCO); Wins Patent Extension Ruling
-
Citi 2Q10 SMID Biotech Earnings Preview: Adjusting AUXL & DNDN Models Ahead of Earnings; Top-Pick is BioMarin (BMRN)
-
Notable Analyst Rating Changes 3/10: GET, DPS, BCS, KSS Upgraded; WMT, DNA, DIS, XTO, BJ Downgraded
-
Citi Maintains a 'Buy' on The Medicines Company (MDCO), Adds to "Top Picks Live" List
-
David Moenning's Daily State of the Markets: 3/3
-
Citi Maintains a 'Buy' on The Medicines Company (MDCO), Removes From Top Picks Live List
-
Citi Maintains a 'Buy' on The Medicines Company (MDCO), Adds Stock to Top Picks Live List
-
Morning Movers 1/13: ZymoGenetics (ZGEN) Up On Bristol-Myers Deal; Lexmark (LXK) Down On Guidance
-
Citi Top Biotech Ideas for 2009 (ALTH, MDCO)
-
Citi Upgrades The Medicines Company (MDCO) to Buy